The DOI matches its Crossref record; 146 of the 146 references it cites were found in a registry or an index.
Regulation of PD-L1 Expression by NF-κB in Cancer
Open accessAbstract
Immune checkpoints are inhibitory receptor/ligand pairs regulating immunity that are exploited as key targets of anti-cancer therapy. Although the PD-1/PD-L1 pair is one of the most studied immune checkpoints, several aspects of its biology remain to be clarified. It has been established that PD-1 is an inhibitory receptor up-regulated by activated T, B, and NK lymphocytes and that its ligand PD-L1 mediates a negative feedback of lymphocyte activation, contributing to the restoration of the steady state condition after acute immune responses. This loop might become detrimental in the presence of either a chronic infection or a growing tumor. PD-L1 expression in tumors is currently used as a biomarker to orient therapeutic decisions; nevertheless, our knowledge about the regulation of PD-L1 expression is limited. The present review discusses how NF-κB, a master transcription factor of inflammation and immunity, is emerging as a key positive regulator of PD-L1 expression in cancer. NF-κB directly induces PD-L1 gene transcription by binding to its promoter, and it can also regulate PD-L1 post-transcriptionally through indirect pathways. These processes, which under conditions of cellular stress and acute inflammation drive tissue homeostasis and promote tissue healing, are largely dysregulated in tumors. Up-regulation of PD-L1 in cancer cells is controlled via NF-κB downstream of several signals, including oncogene- and stress-induced pathways, inflammatory cytokines, and chemotherapeutic drugs. Notably, a shared signaling pathway in epithelial cancers induces both PD-L1 expression and epithelial–mesenchymal transition, suggesting that PD-L1 is part of the tissue remodeling program. Furthermore, PD-L1 expression by tumor infiltrating myeloid cells can contribute to the immune suppressive features of the tumor environment. A better understanding of the interplay between NF-κB signaling and PD-L1 expression is highly relevant to cancer biology and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335
Self-citationFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 2×
“Return to the steady state at the end of immune response is tightly regulated (6, 7), and it is widely recognized that the PD-1/PD-L1 axis plays a central role in physiological immune homeostasis, contributing to the prevention of lymphocyte overactivation and immunopathology (1, 8).”
BackgroundThe M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689
Complex networks orchestrate epithelial–mesenchymal transitions
Thiery, J. P., & Sleeman, J. P. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1835 · Cited by 3,958
Anticancer potential of curcumin: preclinical and clinical studies.
Aggarwal, B. B., Kumar, A. J., & Bharti, A. C. (2003) · PubMed · Cited by 3,017
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp127 · Cited by 2,890
Self-citationMultiple nuclear factors interact with the immunoglobulin enhancer sequences
Sen, R., & Baltimore, D. (1986) · Cell · doi:10.1016/0092-8674(86)90346-6 · Cited by 2,752
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology
Zhang, Q., Lenardo, M. J., & Baltimore, D. (2017) · Cell · doi:10.1016/j.cell.2016.12.012 · Cited by 1,982
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942
The non-canonical NF-κB pathway in immunity and inflammation
Sun, S.-C. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.52 · Cited by 1,891
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,732
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation
Viatour, P., Merville, M.-P., Bours, V., & Chariot, A. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.11.009 · Cited by 1,496
NF‐κB and the link between inflammation and cancer
DiDonato, J. A., Mercurio, F., & Karin, M. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01099.x · Cited by 1,482
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383
Inflammation meets cancer, with NF-κB as the matchmaker
Ben-Neriah, Y., & Karin, M. (2011) · Nature Immunology · doi:10.1038/ni.2060 · Cited by 1,373
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Duration of Nuclear NF-κB Action Regulated by Reversible Acetylation
Chen, L.-F., Fischle, W., Verdin, E., & Greene, W. C. (2001) · Science · doi:10.1126/science.1062374 · Cited by 1,222
Mechanisms and consequences of Jak–STAT signaling in the immune system
Villarino, A. V., Kanno, Y., & O'Shea, J. J. (2017) · Nature Immunology · doi:10.1038/ni.3691 · Cited by 1,221
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147
Hayden, M. S., & Ghosh, S. (2011) · Cell Research · doi:10.1038/cr.2011.13 · Cited by 1,117
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
The IκB kinase (IKK) and NF-κB: key elements of proinflammatory signalling
Karin, M., & Delhase, M. (2000) · Seminars in Immunology · doi:10.1006/smim.2000.0210 · Cited by 955
Hypoxia-induced neutrophil survival is mediated by HIF-1α–dependent NF-κB activity
Walmsley, S. R., Print, C., Farahi, N., Peyssonnaux, C., Johnson, R. S., Cramer, T., Sobolewski, A., Condliffe, A. M., Cowburn, A. S., Johnson, N., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20040624 · Cited by 891
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852 · cited 1×
“Notably, two recent studies, by using a CRISPR-Cas9based wide screening approach, have identified NF-κB as a major determinant of cancer cell resistance against immune attack (39, 40).”
BackgroundStabilization of Snail by NF-κB Is Required for Inflammation-Induced Cell Migration and Invasion
Wu, Y., Deng, J., Rychahou, P. G., Qiu, S., Evers, B. M., & Zhou, B. P. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.016 · Cited by 796
Deubiquitination and Stabilization of PD-L1 by CSN5
Lim, S.-O., Li, C.-W., Xia, W., Cha, J.-H., Chan, L.-C., Wu, Y., Chang, S.-S., Lin, W.-C., Hsu, J.-M., Hsu, Y.-H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.010 · Cited by 793
A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells
Barsoum, I. B., Smallwood, C. A., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0992 · Cited by 767
Limiting inflammation—the negative regulation of NF-κB and the NLRP3 inflammasome
Afonina, I. S., Zhong, Z., Karin, M., & Beyaert, R. (2017) · Nature Immunology · doi:10.1038/ni.3772 · Cited by 759
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M., Cheng, P., Curiel, T., Myers, L., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050930 · Cited by 748
Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M., Wang, H. Y., Wysocka, M., Cheng, M., Ruggeri, B. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810958105 · Cited by 728
Metabolic Reprogramming of Immune Cells in Cancer Progression
Biswas, S. K. (2015) · Immunity · doi:10.1016/j.immuni.2015.09.001 · Cited by 721
Inflammation and EMT: an alliance towards organ fibrosis and cancer progression
López‐Novoa, J. M., & Nieto, M. A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900043 · Cited by 654
Porta, C., Rimoldi, M., Raes, G., Brys, L., Ghezzi, P., Di Liberto, D., Dieli, F., Ghisletti, S., Natoli, G., De Baetselier, P., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809784106 · Cited by 627
Self-citationFc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592
Liu, J., Hamrouni, A., Wolowiec, D., Coiteux, V., Kuliczkowski, K., Hetuin, D., Saudemont, A., & Quesnel, B. (2007) · Blood · doi:10.1182/blood-2006-10-051482 · Cited by 580
(2001) · PubMed · Cited by 557
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 542
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Weber, R., Fleming, V., Hu, X., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 538
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
Azuma, T., Yao, S., Zhu, G., Flies, A. S., Flies, S. J., & Chen, L. (2008) · Blood · doi:10.1182/blood-2007-11-123141 · Cited by 531
Interferon target-gene expression and epigenomic signatures in health and disease
Barrat, F. J., Crow, M. K., & Ivashkiv, L. B. (2019) · Nature Immunology · doi:10.1038/s41590-019-0466-2 · Cited by 530
Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3098 · Cited by 525
Parkes, E. E., Walker, S. M., Taggart, L. E., McCabe, N., Knight, L. A., Wilkinson, R., McCloskey, K. D., Buckley, N. E., Savage, K. I., Salto-Tellez, M., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw199 · Cited by 462
Saccani, A., Schioppa, T., Porta, C., Biswas, S. K., Nebuloni, M., Vago, L., Bottazzi, B., Colombo, M. P., Mantovani, A., & Sica, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1867 · Cited by 455
Self-citationLee, S.-J., Jang, B.-C., Lee, S.-W., Yang, Y.-I., Suh, S.-I., Park, Y.-M., Oh, S., Shin, J.-G., Yao, S., Chen, L., et al. (2006) · FEBS Letters · doi:10.1016/j.febslet.2005.12.093 · Cited by 446
Kufe, D. W. (2013) · Oncogene · doi:10.1038/onc.2012.158 · Cited by 437
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
Zhu, H., Bengsch, F., Svoronos, N., Rutkowski, M. R., Bitler, B. G., Allegrezza, M. J., Yokoyama, Y., Kossenkov, A. V., Bradner, J. E., Conejo-Garcia, J. R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.032 · Cited by 432
Lo Russo, G., Moro, M., Sommariva, M., Cancila, V., Boeri, M., Centonze, G., Ferro, S., Ganzinelli, M., Gasparini, P., Huber, V., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1390 · Cited by 408
Self-citationMandai, M., Hamanishi, J., Abiko, K., Matsumura, N., Baba, T., & Konishi, I. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0224 · Cited by 395
NF-κB and cell-cycle regulation: the cyclin connection
JOYCE, D., ALBANESE, C., STEER, J., FU, M., BOUZAHZAH, B., & PESTELL, R. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00018-6 · Cited by 393
Diskin, B., Adam, S., Cassini, M. F., Sanchez, G., Liria, M., Aykut, B., Buttar, C., Li, E., Sundberg, B., Salas, R. D., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0620-x · Cited by 392
The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
Qin, W., Hu, L., Zhang, X., Jiang, S., Li, J., Zhang, Z., & Wang, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02298 · Cited by 369
Duan, J., Cui, L., Zhao, X., Bai, H., Cai, S., Wang, G., Zhao, Z., Zhao, J., Chen, S., Song, J., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5367 · Cited by 349
Wang, X., Yang, L., Huang, F., Zhang, Q., Liu, S., Ma, L., & You, Z. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.02.006 · Cited by 324
Return to homeostasis: downregulation of NF-κB responses
Ruland, J. (2011) · Nature Immunology · doi:10.1038/ni.2055 · Cited by 322
Roles of the NF- B Pathway in Lymphocyte Development and Function
Gerondakis, S., & Siebenlist, U. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000182 · Cited by 320
Zhang, X., Zeng, Y., Qu, Q., Zhu, J., Liu, Z., Ning, W., Zeng, H., Zhang, N., Du, W., Chen, C., et al. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1161-7 · Cited by 316
Ritprajak, P., & Azuma, M. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2014.11.014 · Cited by 314
Dong, P., Xiong, Y., Yue, J., Hanley, S. J. B., & Watari, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00386 · Cited by 305
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Noguchi, T., Ward, J. P., Gubin, M. M., Arthur, C. D., Lee, S. H., Hundal, J., Selby, M. J., Graziano, R. F., Mardis, E. R., Korman, A. J., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0391 · Cited by 302
Regulation of DNA binding by Rel/NF-κB transcription factors: structural views
Chen, F. E., & Ghosh, G. (1999) · Oncogene · doi:10.1038/sj.onc.1203224 · Cited by 301
NF-κB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer
Grinberg-Bleyer, Y., Oh, H., Desrichard, A., Bhatt, D. M., Caron, R., Chan, T. A., Schmid, R. M., Klein, U., Hayden, M. S., & Ghosh, S. (2017) · Cell · doi:10.1016/j.cell.2017.08.004 · Cited by 297
Bi, X.-W., Wang, H., Zhang, W.-W., Wang, J.-H., Liu, W.-J., Xia, Z.-J., Huang, H.-Q., Jiang, W.-Q., Zhang, Y.-J., & Wang, L. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0341-7 · Cited by 297
Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
Jin, X., Ding, D., Yan, Y., Li, H., Wang, B., Ma, L., Ye, Z., Ma, T., Wu, Q., Rodrigues, D. N., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.10.034 · Cited by 257
Noman, M. Z., Janji, B., Abdou, A., Hasmim, M., Terry, S., Tan, T. Z., Mami-Chouaib, F., Thiery, J. P., & Chouaib, S. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1263412 · Cited by 253
MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer
Maeda, T., Hiraki, M., Jin, C., Rajabi, H., Tagde, A., Alam, M., Bouillez, A., Hu, X., Suzuki, Y., Miyo, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1636 · Cited by 250
PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells
Soliman, H., Khalil, F., & Antonia, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088557 · Cited by 245
Chen, Y., Wang, Q., Shi, B., Xu, P., Hu, Z., Bai, L., & Zhang, X. (2011) · Cytokine · doi:10.1016/j.cyto.2011.06.004 · Cited by 243
Honda, T., Egen, J. G., Lämmermann, T., Kastenmüller, W., Torabi-Parizi, P., & Germain, R. N. (2014) · Immunity · doi:10.1016/j.immuni.2013.11.017 · Cited by 237
NF-kappaB: Two Sides of the Same Coin
Pires, B., Silva, R., Ferreira, G., & Abdelhay, E. (2018) · Genes · doi:10.3390/genes9010024 · Cited by 237
Gowrishankar, K., Gunatilake, D., Gallagher, S. J., Tiffen, J., Rizos, H., & Hersey, P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123410 · Cited by 230
The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
Lu, C., Redd, P. S., Lee, J. R., Savage, N., & Liu, K. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1247135 · Cited by 230
Yu, J., Wang, Y., Yan, F., Zhang, P., Li, H., Zhao, H., Yan, C., Yan, F., & Ren, X. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400833 · Cited by 219
Gao, Y., Yang, J., Cai, Y., Fu, S., Zhang, N., Fu, X., & Li, L. (2018) · International Journal of Cancer · doi:10.1002/ijc.31357 · Cited by 217
Wu, Z.-H., Wong, E. T., Shi, Y., Niu, J., Chen, Z., Miyamoto, S., & Tergaonkar, V. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.010 · Cited by 207
Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome
Uhle, S. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg127 · Cited by 202
Kondo, A., Yamashita, T., Tamura, H., Zhao, W., Tsuji, T., Shimizu, M., Shinya, E., Takahashi, H., Tamada, K., Chen, L., et al. (2010) · Blood · doi:10.1182/blood-2009-12-255125 · Cited by 201
Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel
Gilmore, T. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203222 · Cited by 200
Asgarova, A., Asgarov, K., Godet, Y., Peixoto, P., Nadaradjane, A., Boyer-Guittaut, M., Galaine, J., Guenat, D., Mougey, V., Perrard, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1423170 · Cited by 199
Zhong, X., Tumang, J. R., Gao, W., Bai, C., & Rothstein, T. L. (2007) · European Journal of Immunology · doi:10.1002/eji.200737461 · Cited by 190
MUC1-C Oncoprotein Functions as a Direct Activator of the Nuclear Factor-κB p65 Transcription Factor
Ahmad, R., Raina, D., Joshi, M. D., Kawano, T., Ren, J., Kharbanda, S., & Kufe, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0523 · Cited by 189
Cai, H., Yan, L., Liu, N., Xu, M., & Cai, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109790 · Cited by 175
MUC1 oncoprotein activates the IκB kinase β complex and constitutive NF-κB signalling
Ahmad, R., Raina, D., Trivedi, V., Ren, J., Rajabi, H., Kharbanda, S., & Kufe, D. (2007) · Nature Cell Biology · doi:10.1038/ncb1661 · Cited by 174
Proto, C., Ferrara, R., Signorelli, D., Russo, G. L., Galli, G., Imbimbo, M., Prelaj, A., Zilembo, N., Ganzinelli, M., Pallavicini, L. M., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.03.004 · Cited by 164
Self-citationWong, D., Teixeira, A. S., Oikonomopoulos, S., Humburg, P., Lone, I. N., Saliba, D. G., Siggers, T., Bulyk, M. L., Angelov, D., Dimitrov, S. I., et al. (2011) · Genome biology · doi:10.1186/gb-2011-12-7-r70 · Cited by 159
EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB
Lin, K., Cheng, J., Yang, T., Li, Y., & Zhu, B. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.05.030 · Cited by 152
TGF-β-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth
Standiford, T. J., Kuick, R., Bhan, U., Chen, J., Newstead, M., & Keshamouni, V. G. (2011) · Oncogene · doi:10.1038/onc.2010.619 · Cited by 151
Prescott, J. A., & Cook, S. J. (2018) · Cells · doi:10.3390/cells7090115 · Cited by 151
Senescent cells: Living or dying is a matter of NK cells
Antonangeli, F., Zingoni, A., Soriani, A., & Santoni, A. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0718-299r · Cited by 146
Self-citationFleming, V., Hu, X., Weller, C., Weber, R., Groth, C., Riester, Z., Hüser, L., Sun, Q., Nagibin, V. S., Kirschning, C. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0053 · Cited by 145
Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs
Porta, C., Consonni, F. M., Morlacchi, S., Sangaletti, S., Bleve, A., Totaro, M. G., Larghi, P., Rimoldi, M., Tripodo, C., Strauss, L., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2843 · Cited by 142
Self-citationLucas, J., Hsieh, T., Halicka, H. D., Darżynkiewicz, Z., & WU, J. M. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4512 · Cited by 140
MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer
Bouillez, A., Rajabi, H. N., Jin, C., Samur, M., Tagde, A., Alam, M., Hiraki, M., Maeda, T., Hu, X., Adeegbe, D. O., et al. (2017) · Oncogene · doi:10.1038/onc.2017.47 · Cited by 133
Genome reading by the NF-κB transcription factors
Mulero, M. C., Wang, V. Y., Huxford, T., & Ghosh, G. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz739 · Cited by 133
Wang, W. J., Chapman, N. M., Zhang, B., Li, M., Fan, M., Laribee, R. N., Zaidi, M. R., Pfeffer, L. M., Chi, H., & Wu, Z. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3134 · Cited by 130
MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial–mesenchymal transition
Rajabi, H. N., Alam, M., Takahashi, H., Kharbanda, A., Guha, M., Ahmad, R., & Kufe, D. W. (2013) · Oncogene · doi:10.1038/onc.2013.114 · Cited by 124
The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma
Vrábel, D., Pour, L., & Ševčíková, S. (2019) · Blood Reviews · doi:10.1016/j.blre.2018.11.003 · Cited by 123
Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
van der Vlist, M., Kuball, J. H. E., Radstake, T. R. D. J., & Meyaard, L. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.131 · Cited by 118
The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy
Yuan, W., Zhao, Q., Gao, Z., Lao, X., Lin, W., Chen, D., Mu, M., Huang, C.-X., Liu, Z., Li, B., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127726 · Cited by 118
Zhu, B., Tang, L., Chen, S., Yin, C., Peng, S., Li, X., Liu, T., Liu, W., Han, C., Stawski, L., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0314-0 · Cited by 117
Myeloid-Derived Suppressor Cells: Ductile Targets in Disease
Consonni, F. M., Porta, C., Marino, A., Pandolfo, C., Mola, S., Bleve, A., & Sica, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00949 · Cited by 116
Self-citationNF-κB and Its Role in Checkpoint Control
Betzler, A. C., Theodoraki, M., Schuler, P. J., Döscher, J., Laban, S. A., Hoffmann, T. K., & Brunner, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113949 · Cited by 113
A Role for NF-κB Activation in Perforin Expression of NK Cells Upon IL-2 Receptor Signaling
Zhou, J., Zhang, J. C., Lichtenheld, M. G., & Meadows, G. G. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.3.1319 · Cited by 110
MUC1-C activates the TAK1 inflammatory pathway in colon cancer
Takahashi, H., Jin, C., Rajabi, H. N., Pitroda, S. P., Alam, M., Ahmad, R., Raina, D. B., Hasegawa, M., Suzuki, Y., Tagde, A., et al. (2015) · Oncogene · doi:10.1038/onc.2014.442 · Cited by 104
Harada, K., Dong, X., Estrella, J. S., Correa, A. M., Xu, Y., Hofstetter, W. L., Sudo, K., Onodera, H., Suzuki, K., Suzuki, A., et al. (2017) · Gastric Cancer · doi:10.1007/s10120-017-0760-3 · Cited by 104
Fahy, B. N., Schlieman, M. G., Virudachalam, S., & Bold, R. J. (2004) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2003.12.005 · Cited by 100
Huang, G., Wen, Q., Zhao, Y., Gao, Q., & Bai, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061602 · Cited by 96
Rajabi, H. N., & Kufe, D. W. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.03.003 · Cited by 95
CD40-Mediated Activation of the NF-κB2 Pathway
Hostager, B. S., & Bishop, G. A. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00376 · Cited by 90
Gallagher, S. J., Mijatov, B., Gunatilake, D., Gowrishankar, K., Tiffen, J. C., James, W. F., Jin, L., Pupo, G. M., Cullinane, C. M., McArthur, G. A., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12282 · Cited by 88
Paul, A., Edwards, J., Pepper, C. J., & Mackay, S. P. (2018) · Cells · doi:10.3390/cells7100176 · Cited by 85
LPS promotes the expression of PD‐L1 in gastric cancer cells through NF‐κB activation
Li, H., Xia, J., Zhu, F., Xi, Z., Pan, C., Gu, L., & Tian, Y. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27329 · Cited by 79
Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity
Hamilton, G., & Rath, B. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1294156 · Cited by 72
Mariotti, F., Quatrini, L., Munari, E., Vacca, P., & Moretta, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00910 · Cited by 71
COP9-Associated CSN5 Regulates Exosomal Protein Deubiquitination and Sorting
Liu, Y., Shah, S. V., Xiang, X., Wang, J., Deng, Z.-B., Liu, C., Zhang, L., Wu, J., Edmonds, T. G., Jambor, C., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080861 · Cited by 69
Zhang, N., Tu, J., Wang, X., & Chu, Q. (2019) · Immunotherapy · doi:10.2217/imt-2018-0110 · Cited by 68
Tato, C. M., Mason, N. J., Artis, D., Shapira, S. D., Caamaño, J., Bream, J. H., Liou, H.-C., & Hunter, C. A. (2006) · International Immunology · doi:10.1093/intimm/dxh391 · Cited by 67
Guo, R., Li, Y., Wang, Z., Bai, H., Duan, J., Wang, S., Wang, L., & Wang, J. (2019) · Cancer Science · doi:10.1111/cas.13989 · Cited by 67
NLRP2 Regulates Proinflammatory and Antiapoptotic Responses in Proximal Tubular Epithelial Cells
Rossi, M. N., Pascarella, A., Licursi, V., Caiello, I., Taranta, A., Rega, L. R., Levtchenko, E. N., Emma, F., Benedetti, F. D., & Prencipe, G. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00252 · Cited by 65
Temporal regulation of HIF-1 and NF-κB in hypoxic hepatocarcinoma cells
Jiang, Y., Zhu, Y. J., Wang, X., Gong, J., Hu, C., Guo, B., Zhu, B., & Li, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.3352 · Cited by 64
Vallabhapurapu, S., Powolny‐Budnicka, I., Riemann, M., Schmid, R. M., Paxian, S. A., Pfeffer, K., Körner, H., & Weih, F. (2008) · European Journal of Immunology · doi:10.1002/eji.200737830 · Cited by 57
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes
Fiore, A., Ugel, S., Sanctis, F. D., Sandri, S., Fracasso, G., Trovato, R., Sartoris, S., Solito, S., Mandruzzato, S., Vascotto, F., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07654-4 · Cited by 55
ERβ regulation of NF-κB activation in prostate cancer is mediated by HIF-1
Mak, P., Li, J., Samanta, S., & Mercurio, A. M. (2015) · Oncotarget · doi:10.18632/oncotarget.5377 · Cited by 54
Wang, X., Ni, S., Chen, Q.-Y., Ma, L., Jiao, Z.-X., Wang, C., & Jia, G. (2016) · Cell Biology International · doi:10.1002/cbin.10716 · Cited by 51
Immunoregulatory Molecule B7-H1 (CD274) Contributes to Skin Carcinogenesis
Cao, Y., Zhang, L., Ritprajak, P., Tsushima, F., Youngnak‐Piboonratanakit, P., Kamimura, Y., Hashiguchi, M., & Azuma, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0527 · Cited by 42
MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway
Alam, M., Bouillez, A., Tagde, A., Ahmad, R., Rajabi, H. N., Maeda, T., Hiraki, M., Suzuki, Y., & Kufe, D. W. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0233 · Cited by 42
Clavijo, P. E., & Frauwirth, K. A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100793 · Cited by 40
Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy
Lecis, D., Sangaletti, S., Colombo, M. P., & Chiodoni, C. (2019) · Cancers · doi:10.3390/cancers11050624 · Cited by 37
How Mucosal Epithelia Deal with Stress: Role of NKG2D/NKG2D Ligands during Inflammation
Antonangeli, F., Soriani, A., Cerboni, C., Sciumè, G., & Santoni, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01583 · Cited by 35
Self-citationRosa, F. D., Francesconi, A., Virgilio, A. D., Finocchi, L., Santilio, I., & Barnaba, V. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199812)28:12<3893::aid-immu3893>3.0.co;2-# · Cited by 32
Xiong, H.-Y., Ma, T., Wu, B., Lin, Y., & Tu, Z. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.14.5767 · Cited by 31
Reflections on the field of photoimmunology
Kripke, M. L. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.234 · Cited by 27
Kocikowski, M., Dziubek, K., & Parys, M. (2020) · Cancers · doi:10.3390/cancers12040804 · Cited by 27
Yao, G., Zhang, Q., Doeppner, T. R., Niu, F., Li, Q., Yang, Y., Kuckelkorn, U., Hagemann, N., Li, W., Hermann, D. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4943 · Cited by 19
Rosa, F. D., Serafini, B., Scognamiglio, P., Virgilio, A. D., Finocchi, L., Aloisi, F., & Barnaba, V. (2000) · International Immunology · doi:10.1093/intimm/12.5.711 · Cited by 18
Abruzzese, M. P., Bilotta, M. T., Fionda, C., Zingoni, A., Soriani, A., Petrucci, M. T., Ricciardi, M. R., Molfetta, R., Paolini, R., Santoni, A., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1562-9 · Cited by 18
Self-citationInhibitory checkpoints in human natural killer cells: IUPHAR Review 28
Mariotti, F. R., Quatrini, L., Munari, E., Vacca, P., Tumino, N., Pietra, G., Mingari, M. C., & Moretta, L. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15081 · Cited by 17
Cited by
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
NF‐κB signaling in inflammation and cancer
Zhang, T., Ma, C., Zhang, Z., Zhang, H., & Hu, H. (2021) · MedComm · doi:10.1002/mco2.104 · Cited by 574
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 535
Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IκBα
Guo, D., Tong, Y., Jiang, X., Meng, Y., Jiang, H., Du, L., Wu, Q., Li, S., Luo, S., Li, M., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.08.002 · Cited by 423
Cuollo, L., Antonangeli, F., Santoni, A., & Soriani, A. (2020) · Biology · doi:10.3390/biology9120485 · Cited by 291
Self-citation
Metadata
- Authors
- Antonangeli, F., Natalini, A., Garassino, M. C., Sica, A., Santoni, A., & Di Rosa, F.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-11-25
- Volume
- 11
- Pages
- 584626-584626
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3108832674
- Cited by
- 385
- References
- 146
- FWCI
- 12.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.